Papers
6
Total Citations
103
H-Index
2
About
Baber Syed is a pioneering researcher at the forefront of oral biotherapeutic delivery, specializing in the development of robotic pill (RP) technologies that replace painful injections with a patient-friendly ingestible alternative. His major contributions center on demonstrating the safety, tolerability, and high bioavailability of this platform for delivering complex biologics—including human parathyroid hormone (teriparatide), usteekinumab biosimilars, and follicle-stimulating hormone—directly through the gastrointestinal tract. Syed’s most cited work, “A robotic pill for oral delivery of biotherapeutics” (94 citations), established the clinical feasibility of this approach in healthy subjects, addressing the longstanding challenge of poor patient compliance due to injection-related pain and inconvenience. His subsequent phase 1 studies (2023–2024) have consistently shown that the robotic pill achieves reliable systemic absorption with bioavailability comparable to subcutaneous injection, a breakthrough for chronic disease management. By enabling oral administration of GLP-1 agonists and other biotherapeutics, Syed’s research promises to transform treatment paradigms for diabetes, osteoporosis, and autoimmune disorders, making daily self-care simpler and more accessible for millions of patients worldwide.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6